NEWTOWN, Pa., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a
Company to highlight approaches for studying rigosertib in multiple rare diseases associated with RAS gene at upcoming scientific conference Collaboration with National Cancer Institute (NCI) for evaluation of rigosertib in pediatric rare disease Onconova to host KOL breakfast symposium for
Oral Rigosertib combined with Azacitidine administered to patients with treatment naïve and refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes, demonstrates responses in difficult-to-treat population • The combination may overcome hypomethylating agent resistance; further
NEWTOWN, Pa., June 13, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced
Bone marrow response to rigosertib was evaluated as a surrogate for survival in this trial of 64 patients who had previously failed Hypomethylating Agent therapy 22% of patients achieved marrow complete response and 47% of patients in the study achieved disease stabilization.
Clinical and Non-clinical Data Evaluating Oral Rigosertib Plus Azacitidine Combination Therapy SymBio, Onconova's Partner in Japan, to Present Phase 1 Data Evaluating Oral Rigosertib as a Single Agent NEWTOWN, Pa., May 22, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 18, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced details relating to a
NEWTOWN, Pa., May 15, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes, today provided a
